A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy
Abstract Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor. It is frequently used in cats with hypertrophic cardiomyopathy (HCM) to prevent thromboembolic complication...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ddb2a51e34504216b33792c1c628f25d |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ddb2a51e34504216b33792c1c628f25d |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ddb2a51e34504216b33792c1c628f25d2021-12-02T17:41:09ZA genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy10.1038/s41598-021-91372-32045-2322https://doaj.org/article/ddb2a51e34504216b33792c1c628f25d2021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91372-3https://doaj.org/toc/2045-2322Abstract Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor. It is frequently used in cats with hypertrophic cardiomyopathy (HCM) to prevent thromboembolic complications. However, significant interpatient variability of the response to clopidogrel therapy has been suspected. In this study, we assessed the impact of single nucleotide polymorphisms (SNPs) within ADP receptor (P2RY1, P2RY12) and cytochrome P450 isoenzyme (CYP2C41) genes on platelet inhibition by clopidogrel administration in cats with HCM. Forty-nine cats completed the study, and blood samples were obtained before and after clopidogrel therapy to assess the degree of platelet inhibition based on flow cytometry and whole blood platelet aggregometry. Plasma concentrations of clopidogrel metabolites were measured after the last dose of clopidogrel. Whole blood platelet aggregometry revealed a significant reduction of platelet inhibition by clopidogrel in cats with the P2RY1:A236G and the P2RY12:V34I variants. The association with the P2RY1:A236G variant and clopidogrel resistance remained significant after adjustment for multiple comparisons. This study demonstrated that a genetic polymorphism in the P2RY1 gene altered response to clopidogrel therapy and suggests that clinicians may consider alternative or additional thromboprophylactic therapy in cats with the P2RY1:A236G variant.Yu UedaRonald H. L. LiNghi NguyenEric S. OntiverosSamantha L. KovacsMaureen S. OldachKaren M. VernauMichael H. CourtJoshua A. SternNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-13 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Yu Ueda Ronald H. L. Li Nghi Nguyen Eric S. Ontiveros Samantha L. Kovacs Maureen S. Oldach Karen M. Vernau Michael H. Court Joshua A. Stern A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| description |
Abstract Clopidogrel is converted to its active metabolite by cytochrome P450 isoenzymes and irreversibly inhibits platelet activation by antagonizing the adenosine-diphosphate (ADP) receptor. It is frequently used in cats with hypertrophic cardiomyopathy (HCM) to prevent thromboembolic complications. However, significant interpatient variability of the response to clopidogrel therapy has been suspected. In this study, we assessed the impact of single nucleotide polymorphisms (SNPs) within ADP receptor (P2RY1, P2RY12) and cytochrome P450 isoenzyme (CYP2C41) genes on platelet inhibition by clopidogrel administration in cats with HCM. Forty-nine cats completed the study, and blood samples were obtained before and after clopidogrel therapy to assess the degree of platelet inhibition based on flow cytometry and whole blood platelet aggregometry. Plasma concentrations of clopidogrel metabolites were measured after the last dose of clopidogrel. Whole blood platelet aggregometry revealed a significant reduction of platelet inhibition by clopidogrel in cats with the P2RY1:A236G and the P2RY12:V34I variants. The association with the P2RY1:A236G variant and clopidogrel resistance remained significant after adjustment for multiple comparisons. This study demonstrated that a genetic polymorphism in the P2RY1 gene altered response to clopidogrel therapy and suggests that clinicians may consider alternative or additional thromboprophylactic therapy in cats with the P2RY1:A236G variant. |
| format |
article |
| author |
Yu Ueda Ronald H. L. Li Nghi Nguyen Eric S. Ontiveros Samantha L. Kovacs Maureen S. Oldach Karen M. Vernau Michael H. Court Joshua A. Stern |
| author_facet |
Yu Ueda Ronald H. L. Li Nghi Nguyen Eric S. Ontiveros Samantha L. Kovacs Maureen S. Oldach Karen M. Vernau Michael H. Court Joshua A. Stern |
| author_sort |
Yu Ueda |
| title |
A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| title_short |
A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| title_full |
A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| title_fullStr |
A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| title_full_unstemmed |
A genetic polymorphism in P2RY 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| title_sort |
genetic polymorphism in p2ry 1 impacts response to clopidogrel in cats with hypertrophic cardiomyopathy |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/ddb2a51e34504216b33792c1c628f25d |
| work_keys_str_mv |
AT yuueda ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT ronaldhlli ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT nghinguyen ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT ericsontiveros ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT samanthalkovacs ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT maureensoldach ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT karenmvernau ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT michaelhcourt ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT joshuaastern ageneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT yuueda geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT ronaldhlli geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT nghinguyen geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT ericsontiveros geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT samanthalkovacs geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT maureensoldach geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT karenmvernau geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT michaelhcourt geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy AT joshuaastern geneticpolymorphisminp2ry1impactsresponsetoclopidogrelincatswithhypertrophiccardiomyopathy |
| _version_ |
1718379731790856192 |